Abstracts tagged "Familial Mediterranean fever and interleukins (IL)"

Abstract Number: 1418 • 2018 ACR/ARHP Annual Meeting
External Validation of the Autoinflammatory Disease Activity Index (AIDAI) in Patients with Colchicine-Resistant FMF, Hids/Mkd, and TRAPS: Results from a Pivotal, Phase 3 Trial of Canakinumab
Isabelle Koné-Paut¹, Maryam Piram², Susanne Benseler³, Jasmin B. Kuemmerle-Deschner⁴, Annette F. Jansson⁵, Itzhak Rosner⁶, Alberto Tommasini⁷, Sara Murias⁸, Omer Karadag⁹, Jeremy Levy¹⁰, Serge Smeets¹¹ and Fabrizio De Benedetti¹², ¹APHP, CHU de Bicêtre, University of Paris SUD, Paris, France, ²Pediatrics, APHP, CHU de Bicêtre, University of Paris SUD, Paris, France, ³Alberta Children's Hospital, Calgary, AB, Canada, ⁴Pediatrics, University Hospital Tübingen, Tübingen, Germany, ⁵Ludwig Maximilian University, Munich, Germany, ⁶Bnai-Zion Medical Center, Haifa, Israel, ⁷Department of Internal Medicine, Università Cattolica Sacro Cuore, Rome, Italy, ⁸Hospital Infantil La Paz, Madrid, Spain, ⁹Rheumatology, Hacettepe University, Faculty of Medicine, Ankara, Turkey, ¹⁰BIOP, Reinach, AR, Switzerland, ¹¹Novartis Pharma B.V., Arnhem, Netherlands, ¹²IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: AIDAI is a novel and unique, validated patient (pt)-reported assessment tool to evaluate disease activity in familial Mediterranean fever (FMF), hyper-IgD syndrome/mevalonate kinase deficiency…
Abstract Number: 2658 • 2012 ACR/ARHP Annual Meeting
Correlation Between Mefv Genotype and Interleukin (IL)1β secretion and Role of the nlr Family Pyrin Domain Containing 3 (Nlrp3) Inflammasome in Patients with Familial Mediterranean Fever (FMF)
Alessia Omenetti¹, Sonia Carta², Delfino Laura², Alberto Martini³, Anna Rubartelli⁴ and Marco Gattorno¹, ¹Pediatrics II Unit G Gaslini Institute, Genoa, Italy, ²Cell Biology, lST-San Martino, Genoa, Italy, ³Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ⁴lST-San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: Familial Mediterranean Fever (FMF) is an autoinflammatory disease due to mutations of MEFV gene which encodes for Pyrin. FMF does not behave as a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].